5-methyl-2,5-diazatetracyclo[13.4.0.0^{2,7}.0^{8,13}]nonadeca-1(15),8(13),9,11,16,18-hexaene

• ChemBase编号: 4416
• 分子式: C18H20N2
• 平均质量: 264.3648
• 单一同位素质量: 264.16264865
• SMILES: N12C(CN(CC1)C)c1c(Cc3c2cccc3)cccc1
• Canonical SMILES: CN1CCN2C(C1)c1ccccc1Cc1c2cccc1
• InChI: InChI=1S/C18H20N2/c1-19-10-11-20-17-9-5-3-7-15(17)12-14-6-2-4-8-16(14)18(20)13-19/h2-9,18H,10-13H2,1H3
• InChIKey: UEQUQVLFIPOEMF-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: 5-methyl-2,5-diazatetracyclo[13.4.0.0^{2,7}.0^{8,13}]nonadeca-1(15),8(13),9,11,16,18-hexaene
• IUPAC传统名: 5-methyl-2,5-diazatetracyclo[13.4.0.0^{2,7}.0^{8,13}]nonadeca-1(15),8(13),9,11,16,18-hexaene
• 商标名: Bolvidon; Norval; Tolvan
• 别名: Mianseryna [polish]; Mianserinum [inn-latin]; Mianserine [inn-french]; Mianserina [inn-spanish]; Mianserine; Mianserin

登记号

• CAS号: 24219-97-4
• PubChem SID: 46508096; 160967848
• PubChem CID: 4184

理论计算性质

JChem

• 质子受体: 2
• 质子供体: 0
• LogD (pH = 5.5): 2.3987954
• LogD (pH = 7.4): 3.7070787
• Log P: 3.8311977
• 摩尔折射率: 84.4987 cm^3
• 极化性: 32.159184 Å^3
• 极化表面积: 6.48 Å^2
• 可自由旋转的化学键: 0
• 里宾斯基五规则: true

ALOGPS 2.1

• Log P: 3.52
• LOG S: -3.06
• 溶解度: 2.32e-01 g/l

详细说明

DrugBank - DB06148

• Drug Groups: approved
• Description: A tetracyclic compound with antidepressant effects. Mianserin was previously available internationally, however in most markets it has been phased out in favor of Mirtazapine.
• Indication: For the treatment of depression.
• Pharmacology: Mianserin is a tetracyclic antidepressant that has antihistaminic and hypnosedative, but almost no anticholinergic, effect. It is a weak inhibitor of norepinephrine reuptake and strongly stimulates the release of norepinephrine. Interactions with serotonin receptors in the central nervous system have also been found. Its effect is usually noticeable after one to three weeks. Mianserin may cause drowsiness and hematological problems.
• Toxicity: Oral rat LD₅₀: 780mg/kg
• Affected Organisms: Humans and other mammals
• Biotransformation: Hepatic.
• Absorption: Absorbed following oral administration.
• Half Life: 10-17 hours
• Protein Binding: 90%
• References: Koyama E, Chiba K, Tani M, Ishizaki T: Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers. J Pharmacol Exp Ther. 1996 Jul;278(1):21-30. [Pubmed] ; de Boer TH, Nefkens F, van Helvoirt A, van Delft AM: Differences in modulation of noradrenergic and serotonergic transmission by the alpha-2 adrenoceptor antagonists, mirtazapine, mianserin and idazoxan. J Pharmacol Exp Ther. 1996 May;277(2):852-60. [Pubmed] ; Kelder J, Funke C, De Boer T, Delbressine L, Leysen D, Nickolson V: A comparison of the physicochemical and biological properties of mirtazapine and mianserin. J Pharm Pharmacol. 1997 Apr;49(4):403-11. [Pubmed]
• External Links: Wikipedia

参考文献

• Koyama E, Chiba K, Tani M, Ishizaki T: Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers. J Pharmacol Exp Ther. 1996 Jul;278(1):21-30. Pubmed
• de Boer TH, Nefkens F, van Helvoirt A, van Delft AM: Differences in modulation of noradrenergic and serotonergic transmission by the alpha-2 adrenoceptor antagonists, mirtazapine, mianserin and idazoxan. J Pharmacol Exp Ther. 1996 May;277(2):852-60. Pubmed
• Kelder J, Funke C, De Boer T, Delbressine L, Leysen D, Nickolson V: A comparison of the physicochemical and biological properties of mirtazapine and mianserin. J Pharm Pharmacol. 1997 Apr;49(4):403-11. Pubmed